GlassScriptPhysician profile
Jeffrey W Bunning
NPI 1306956776
$2,397.94
in general payments reported to CMS, 2019-2025
25 companies · $693 in 2025
The $693 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $137 · 2021: $143 · 2022: $334 · 2023: $322 · 2024: $454 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,468.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $352.23 | 2022-2025 | Rocklatan, Clareon, Eysuvis |
| Harrow Eye, LLC | $267.50 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $249.62 | 2019-2023 | |
| Glaukos Corporation | $205.83 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Oyster Point Pharma, INC. | $168.38 | 2023-2025 | Tyrvaya |
| Bausch & Lomb Americas INC. | $159.59 | 2023-2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $149.37 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $126.80 | 2024-2025 | Xdemvy |
| Allergan, INC. | $99.13 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $77.89 | 2022-2024 | Acthar |
| Dompe US, INC. | $62.89 | 2024-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $61.79 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $58.77 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $43.82 | 2024 | Tepezza |
| Rayner Intraocular Lenses Limited | $40.82 | 2022-2025 | Rayone Spheric, Rayone Aspheric, Rayner Cataract Set 1 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $37.95 | 2019 | |
| Merz Pharmaceuticals, LLC | $35.43 | 2023-2025 | Xeomin |
| Sun Pharmaceutical Industries INC. | $34.47 | 2019-2024 | |
| Horizon Therapeutics Plc | $33.86 | 2023 | Tepezza |
| Abbvie INC. | $33.65 | 2023-2025 | Durysta |
| Travere Therapeutics, INC. | $24.00 | 2022 | |
| Sight Sciences, INC. | $23.77 | 2024 | Omni Surgical System |
| Biotissue Holdings INC. | $18.16 | 2021 | |
| Vanda Pharmaceuticals INC. | $17.70 | 2020 | |
| Ocular Therapeutix, INC. | $14.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Bunning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.